I can't comment on the least mean squared numbers, but will say this. The releases I have read, have been straight forward, very easy to understand and never misleading.
If you don't understand the difference between a primary and a secondary end point, or a trial that has been stated by the company to most likely be 1 of 2 required.... Its got to be your interpretation of the results that is causing you grief, and I would be careful taking advise from people on this chat board to try and read between the lines.
Ann: Rexlemestrocel-L Improves LVEF, Preceding Reduction in MACE, page-139
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.12 |
Change
0.015(1.36%) |
Mkt cap ! $1.278B | |||
| Open | High | Low | Value | Volume |
| $1.13 | $1.16 | $1.10 | $7.169M | 6.411M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 7296 | $1.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.12 | 43068 | 1 |
View Market Depth
| Last trade - 16.10pm 08/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |